Long-term antiepileptic treatment with histone deacetylase inhibitors may reduce the risk of prostate cancer

European Journal of Cancer Prevention

Volumn 21, Issue 1, 2012, Pages 55-64

  Stettner, Mark ^a   Krämer, Günter ^c   Strauss, Arne ^b   Kvitkina, Tatjana ^a   Ohle, Sandra ^c   Kieseier, Bernd C ^a   Thelen, Paul ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c SWISS EPILEPSY CENTER   (Switzerland)

Author keywords

Carbamazepine; Lamotrigine; Levetiracetam; Oxcarbazepine; Prostate specific antigen; Valproic acid

Indexed keywords

CARBAMAZEPINE; ETIRACETAM; HISTONE DEACETYLASE INHIBITOR; LAMOTRIGINE; MESSENGER RNA; OXCARBAZEPINE; PROSTATE SPECIFIC ANTIGEN; VALPROIC ACID;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER RISK; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR CELL;

AGED; ANTICONVULSANTS; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; VALPROIC ACID;

EID: 82555205335     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e32834a7e6f     Document Type: Article

References (47)

1. Abbas A, Gupta S (2008). The role of histone deacetylases in prostate cancer. Epigenetics 3:300-309.
2. Atmaca A, Al-Batran SE, Maurer A, Neumann A, Heinzel T, Hentsch B, et al. (2007). Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer 97:177-182. (Pubitemid 47057472)
3. Batta K, Das C, Gadad S, Shandilya J, Kundu TK (2007). Reversible acetylation of non histone proteins: role in cellular function and disease. Subcell Biochem 41:193-212.
4. Bosland MC, McCormick DL, Melamed J, Walden PD, Zeleniuch-Jacquotte A, Lumey LH (2002). Chemoprevention strategies for prostate cancer. Eur J Cancer Prev 11 (Suppl 2):S18-S27. (Pubitemid 35265859)
5. Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gellei B, et al. (1977). Latent carcinoma of prostate at autopsy in seven areas. The international agency for research on cancer, Lyons, France. Int J Cancer 20:680-688.
6. Cang S, Ma Y, Liu D (2009). New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. J Hematol Oncol 2:22.
7. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. (1994). Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol 151:1283-1290. (Pubitemid 24121936)
8. Chinnaiyan P, Varambally S, Tomlins SA, Ray S, Huang S, Chinnaiyan AM, et al. (2006). Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition. Int J Cancer 118:1041-1050. (Pubitemid 43157683)
9. Cooner WH, Mosley BR, Rutherford CL Jr., Beard JH, Pond HS, Terry WJ, et al. (1990). Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 143:1146-1152; discussion 52-54.
10. De Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, et al. (2002). DD3(PCA3): a very sensitive and specific marker to detect prostate tumors. Cancer Res 62:2695-2698. (Pubitemid 34462754)
11. Eisinger F, Blay JY, Pivot X, Morere JF, Coscas Y, Calazel-Benque A, et al. (2011). Screening for prostate cancer: growth without control. Eur J Cancer Prev 20 (Suppl 1):S33-S35.
12. Ellis WJ, Chetner MP, Preston SD, Brawer MK (1994). Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. J Urol 152:1520-1525. (Pubitemid 24326300)
13. Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M, Bialer M (2004). The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 45:737-744. (Pubitemid 38890970)
14. Eyal S, Yagen B, Shimshoni J, Bialer M (2005). Histone deacetylases inhibition and tumor cells cytotoxicity by CNS-active VPA constitutional isomers and derivatives. Biochem Pharmacol 69:1501-1508. (Pubitemid 40602450)
15. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P (2007). Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18:581-592. (Pubitemid 46359643)
16. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, et al. (1994). Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 54:2861-2864. (Pubitemid 24187763)
17. Gallinari P, Di Marco S, Jones P, Pallaoro M, Steinkuhler C (2007). HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res 17:195-211. (Pubitemid 46438722)
18. Gann PH, Hennekens CH, Stampfer MJ (1995). A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 273:289-294.
19. Glozak MA, Sengupta N, Zhang X, Seto E (2005). Acetylation and deacetylation of non-histone proteins. Gene 363:15-23. (Pubitemid 41691888)
20. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, et al. (2001). Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. Embo J 20:6969-6978. (Pubitemid 34062289)
21. Haese A, Graefen M, Palisaar J, Huland E, Huland H (2003). Serum markers for early detection and staging of prostate cancer: status report on current and future markers. Urologe A 42:1172-1187. (Pubitemid 37176290)
22. Haese A, De la Taille A, Van Poppel H, Marberger M, Stenzl A, Mulders PF, et al. (2008). Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 54:1081-1088.
23. Hammerer P, Huland H (1994). Systematic sextant biopsies in 651 patients referred for prostate evaluation. J Urol 151:99-102. (Pubitemid 2004486)
24. Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, et al. (1999). Cancer surveillance series: interpreting trends in prostate cancer part I. Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 91:1017-1024. (Pubitemid 29293040)
25. Horvath LG, Henshall SM, Lee CS, Head DR, Quinn DI, Makela S, et al. (2001). Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res 61:5331-5335. (Pubitemid 32694904)
26. Hsing AW, Chu LW, Stanczyk FZ (2008). Androgen and prostate cancer: is the hypothesis dead? Cancer Epidemiol Biomarkers Prev 17:2525-2530.
27. Jemal A, Center MM, DeSantis C, Ward EM (2010). Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19:1893-1907.
28. Jemal A, Bray F, Center MM, Ferlay J,Ward E, Forman D (2011). Global cancer statistics. CA Cancer J Clin 61:69-90.
29. Knudsen KE, Penning TM (2010). Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab 21:315-324.
30. Landers KA, Burger MJ, Tebay MA, Purdie DM, Scells B, Samaratunga H, et al. (2005). Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer 114:950-956.
31. Li LC, Carroll PR, Dahiya R (2005). Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst 97: 103-115. (Pubitemid 40277090)
32. Lindemann RK, Gabrielli B, Johnstone RW (2004). Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle 3:779-788. (Pubitemid 40187911)
33. Ma X, Ezzeldin HH, Diasio RB (2009). Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 69:1911-1934.
34. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. (2007). The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 369:1016-1026. (Pubitemid 46436125)
35. Pasquali D, Rossi V, Esposito D, Abbondanza C, Puca GA, Bellastella A, et al. (2001). Loss of estrogen receptor beta expression in malignant human prostate cells in primary cultures and in prostate cancer tissues. J Clin Endocrinol Metab 86:2051-2055. (Pubitemid 32472918)
36. Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B, et al. (2006). Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res 12:634-642. (Pubitemid 43166159)
37. SakrWA, Haas GP, Cassin BF, Pontes JE, Crissman JD (1993). The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 150:379-385. (Pubitemid 23215874)
38. Shabbeer S, Kortenhorst MS, Kachhap S, Galloway N, Rodriguez R, Carducci MA (2007). Multiple molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. Prostate 67: 1099-1110. (Pubitemid 46983339)
39. Shahbazian MD, Grunstein M (2007). Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem 76:75-100.
40. Stettner M, Kaulfuss S, Burfeind P, Schweyer S, Strauss A, Ringert RH, et al. (2007). The relevance of estrogen receptor-beta expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment. Mol Cancer Ther 6:2626-2633. (Pubitemid 350058143)
41. Thelen P, Schweyer S, Hemmerlein B,Wuttke W, Seseke F, Ringert RH (2004). Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells. Int J Oncol 24:25-31.
42. Thompson IM Jr., Leach RJ, Ankerst DP (2010). Prostate cancer detection: a view of the future. Eur Urol [Epub ahead of print].
43. Ulmert D, Cronin AM, Bjork T, O'Brien MF, Scardino PT, Eastham JA, et al. (2008). Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a casecontrol study. BMC Med 6:6.
44. Veneziano S, Pavlica P, Querze R, Nanni G, Lalanne MG, Vecchi F (1990). Correlation between prostate-specific antigen and prostate volume, evaluated by transrectal ultrasonography: usefulness in diagnosis of prostate cancer. Eur Urol 18:112-116. (Pubitemid 20300958)
45. Waltregny D, North B, Van Mellaert F, De Leval J, Verdin E, Castronovo V (2004). Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class I HDAC profiles between epithelial and stromal cells. Eur J Histochem 48:273-290.
46. Watson JA, McKenna DJ, Maxwell P, Diamond J, Arthur K, McKelvey-Martin VJ, et al. (2010). Hyperacetylation in prostate cancer induces cell cycle aberrations, chromatin reorganization and altered gene expression profiles. J Cell Mol Med 14:1668-1682.
47. Welsbie DS, Xu J, Chen Y, Borsu L, Scher HI, Rosen N, et al. (2009). Histone deacetylases are required for androgen receptor function in hormonesensitive and castrate-resistant prostate cancer. Cancer Res 69:958-966.